Enterprise Value
-155M
Cash
255M
Avg Qtr Burn
-25.29M
Short % of Float
4.54%
Insider Ownership
9.17%
Institutional Own.
84.34%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PRT3645 (CDK4/6 inhibitor) Details Glioblastoma, Head and neck cancer, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout | |
PRT543 (PRMT5 inhibitor) Details Solid tumor/s, Myelodysplastic syndrome, Myelofibrosis, Cancer | Phase 1 Data readout | |
PRT3789 Details Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
PRT2527 (CDK9 inhibitor) Details Acute myeloid leukemia, Solid tumor/s, Hematologic malignancies | Phase 1 Data readout | |
PRT1419 (MCL1 inhibitor) Details Hematologic malignancies, Relapsed/refractory acute myeloid leukemia, B-cell malignancies, Solid tumor/s | Phase 1 Update | |
PRT811 (PRMT5 inhibitor) Details Glioblastoma, Cancer, primary central nervous system lymphomas | Failed Discontinued |